+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation



Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation



Journal of Cardiology 57(3): 303-310



N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a diagnostic biomarker for patients with congestive heart failure (CHF). However, the clinical significance of measurements of NT-proBNP levels in patients with coronary artery disease (CAD) who have undergone drug-eluting stent (DES) implantation has not been fully elucidated. We recruited 280 patients with documented CAD who were scheduled for elective coronary intervention and also age- and gender-matched 140 healthy subjects. Subjects with acute coronary syndrome, ongoing CHF, and stage IV or V chronic kidney disease were excluded. We measured the plasma NT-proBNP levels and followed the CAD patients who have undergone DES implantation for up to 62 months until occurrence of major adverse cardiovascular events (MACE). Plasma NT-proBNP levels were significantly higher in CAD patients compared to control subjects (p<0.0001). In the CAD group, 25 patients developed MACE and the NT-proBNP levels in the MACE group were significantly higher compared to that in the non-MACE group (p=0.005). After adjusting for the confounding factors, high NT-proBNP levels were observed to be independent factors for CAD (p<0.0001) and MACE (p=0.021). These results demonstrated that the measurements of NT-proBNP levels may be useful in identifying high-risk subjects among CAD patients who have undergone elective DES implantation.

(PDF emailed within 0-6 h: $19.90)

Accession: 052131804

Download citation: RISBibTeXText

PMID: 21388786

DOI: 10.1016/j.jjcc.2011.01.015


Related references

Soluble CD40 ligand release in patients with stable coronary artery disease during elective stent implantation: effect of drug-eluting stent over bare metal stent. Turk Kardiyoloji Dernegi Arsivi 41(8): 675-682, 2015

Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation. Mediators of Inflammation 2014: 963096-963096, 2015

Risk factors of cardiac troponin T elevation in patients with stable coronary artery disease after elective coronary drug-eluting stent implantation. Clinical Cardiology 34(12): 768-773, 2012

Association of N-terminal-Pro-B-type Natriuretic Peptide Levels and 2 years Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention with Drug-eluting Stents in Asian Populations. American Journal of Cardiology 111(7): 80b-81b, 2013

Association of N-terminal-pro-B-type natriuretic peptide levels and 2 years clinical outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian populations. European Heart Journal 34(Suppl 1): P4827-P4827, 2013

Effect of remote ischemic preconditioning in the elderly patients with coronary artery disease with diabetes mellitus undergoing elective drug-eluting stent implantation. Angiology 65(8): 660-666, 2014

The effect of percutaneous coronary revascularization on plasma N-terminal pro-B-type natriuretic peptide levels in stable coronary artery disease. Indian Heart Journal 70(2): 282-288, 2018

Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function. American Journal of Medicine 116(8): 517-523, 2004

Impact of metabolic syndrome on clinical outcomes after drug-eluting stent implantation in patients with coronary artery disease. Angiology 62(6): 440-446, 2011

Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. American Journal of Cardiology 95(5): 553-557, 2005

Assessment of novel biomarkers for restenosis occurrence after drug-eluting stent implantation in patients with stable coronary artery disease and type 2 diabetes mellitus. Atherosclerosis 263: E121-E122, 2018

Assessment of novel biomarkers for restenosis occurrence after drug-eluting stent implantation in patients with stable coronary artery disease and type 2 diabetes mellitus. Atherosclerosis 263: E121-E122, 2017

Are plasma levels of atrial natriuretic peptide, N-terminal ProANP, and brain natriuretic peptide affected by the presence of coronary artery disease?. Circulation 109(25): E331; Author Reply E331-E331; Author Reply E331, 2004

AS-203 Comparison of Clinical Outcome between Bare-Metal Stent and Drug-Eluting Stent Implantation in Large Vessel Coronary Artery Disease. American Journal of Cardiology 107(8-Supp-S): 76-0, 2011

Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry. Journal of the American College of Cardiology 51(23): 2212-2219, 2008